Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

Clinical trial NCT04710641 · COMPLETED

Trial details

NCT number: NCT04710641
Sponsor: Mina Alpha Limited
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Hepatitis B Hepatitis C

Start date: 2022-01-01
Primary completion: 2025-01-25
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.